摘要
目的系统评价中成药肿瘤用药药物经济学研究的质量。方法计算机检索CNKI、WanFang Data、VIP、SinoMed、PubMed、Web of Science、Cochrane Library和EMbase数据库,搜集有关中成药肿瘤用药的药物经济学研究,检索时限均从建库至2022年9月30日。采用卫生经济学评价报告标准共识2022(CHEERS2022)和卫生经济研究质量评价(QHES)对报告质量和方法学质量进行评价。结果共纳入25个研究,CHEERS2022平均符合率为40.09%,QHES平均评分为53.2分。结论现有中成药肿瘤用药的药物经济学研究数量少,研究质量较差。建议未来加强科研机构和医院的合作,规范开展中成药肿瘤用药的药物经济学研究,为中成药应用于肿瘤疾病提供卫生决策依据。
Objective To systematically evaluate the quality of published pharmacoeconomics studies on Chinese patent medicines for neoplasms.Methods Datasets including CNKI,WanFang Data,VIP,SinoMed,PubMed,Web of Science,Cochrane Library,and EMbase were searched to collect pharmacoeconomics studies of Chinese patent medicines in neoplasms from the establishment of the database to September 30,2022.Consolidated health economic evaluation reporting standards 2022(CHEERS 2022)and quality of health economics studies(QHES)were used to evaluate the reporting quality and methodological quality.Results A total of 25 studies were included,with an average CHEERS 2022 coincidence rate of 40.09%and an average QHES score of 53.2.Conclusion The quantity and quality of pharmacoeconomics studies on Chinese patent medicines in neoplasms are insufficient and flawed.It is suggested to strenthen the collaboration between scientific research institutions and hospitals and standardize the pharmacoeconomics studies on Chinese patent medicines in neoplasms to provide hygienic decision-making evidence for Chinese patent medicines in neoplasms.
作者
王巍力
张海力
梁宁
胡紫腾
杨璐
宋填
宗星煜
曹文杰
杨一玖
王丁熠
陈雅馨
王燕平
史楠楠
WANG Weili;ZHANG Haili;LIANG Ning;HU Ziteng;YANG Lu;SONG Tian;ZONG Xingyu;CAO Wenjie;YANG Yijiu;WANG Dingyi;CHEN Yaxin;WANG Yanping;SHI Nannan(Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,P.R.China)
出处
《中国循证医学杂志》
CSCD
北大核心
2023年第5期561-568,共8页
Chinese Journal of Evidence-based Medicine
基金
国家自然科学基金项目(编号:82174532)
中国中医科学院科技创新工程项目(编号:CI2021A00702)
中国中医科学院“中医临床基础学科”创新团队(编号:CI2021B00301)
国家中医药管理局标准化专项项目(编号:GZT-FJS-2020-203)。
关键词
中成药
肿瘤
药物经济学
质量评价
Chinese patent medicine
Neoplasm
Pharmacoeconomics
Quality evaluation
